Alleviant Medical

Executive Summary

Alleviant Medical is a private medical device company developing the Alleviant System, a novel, minimally invasive interatrial shunt therapy for heart failure patients. Unlike traditional shunts, the Alleviant System reduces excess pressure in the heart without leaving a permanent implant, potentially mitigating long-term complications. The company is currently evaluating its technology through two FDA-approved clinical trials: ALLAY-HF (for heart failure with preserved ejection fraction) and ALLAY-HFrEF (for heart failure with reduced ejection fraction). Both trials are designed to assess the safety and efficacy of the system in improving hemodynamics and clinical outcomes. Alleviant's approach addresses a significant unmet need in the large and growing heart failure market, where existing therapies often provide limited benefit. If successful, the Alleviant System could offer a differentiated, reversible treatment option that avoids the risks associated with permanent implants. The company's progress through FDA-approved trials positions it for potential regulatory submissions within the next few years. With strong clinical rationale and a focus on patient-centric innovation, Alleviant Medical represents a compelling opportunity in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q4 2026Completion of Enrollment in ALLAY-HF Trial70% success
• Q3 2026Interim Data Readout from ALLAY-HFrEF Trial65% success
• Q1 2027FDA Breakthrough Device Designation Update or Regulatory Milestone80% success